Polymyalgia Rheumatica

Comprehensive Clinical Guide: Polymyalgia Rheumatica (PMR)

Polymyalgia Rheumatica (PMR) is a systemic inflammatory rheumatic condition characterized by proximal muscle pain, stiffness, and constitutional symptoms, predominantly affecting individuals over the age of 50. As an inflammatory disorder of the musculoskeletal system, it represents one of the most common inflammatory diseases in the elderly population. While often managed in primary care, its association with Giant Cell Arteritis (GCA) necessitates a high index of clinical suspicion and a systematic approach to diagnosis and long-term management.

1. Clinical Definition and Overview

Polymyalgia Rheumatica is clinically defined as a syndrome of unknown etiology that manifests as bilateral aching and morning stiffness in the shoulder girdle, pelvic girdle, and neck. The symptoms are frequently severe, often debilitating, and show a dramatic response to low-dose systemic corticosteroids.

Epidemiological Profile

• Age of Onset: Rarely occurs before age 50; peak incidence is between 70 and 80 years.
• Gender Predominance: Women are affected approximately two to three times more frequently than men.
• Ethnic Distribution: Highest prevalence is observed in populations of Northern European descent.

2. Etiology and Pathophysiology

The exact etiology of PMR remains elusive, though current research points to a complex interplay between genetic predisposition, environmental triggers, and age-related immunosenescence.

Pathophysiological Mechanisms

The hallmark of PMR is synovitis and bursitis rather than primary myopathy. Advanced imaging (MRI and PET/CT) has revolutionized our understanding of PMR, shifting the focus from the muscle to the periarticular structures.

1. Synovitis and Bursitis: Inflammation is primarily localized to the subacromial/subdeltoid bursae, the hip trochanteric bursae, and the glenohumeral joints.
2. Cytokine Cascade: There is a significant upregulation of interleukin-6 (IL-6), which correlates directly with the severity of systemic inflammation and the acute-phase response.
3. T-Cell Activation: Evidence suggests an oligoclonal expansion of T-cells, indicating an antigen-driven immune response, potentially triggered by a viral infection or other environmental stressors in genetically susceptible individuals (notably those with HLA-DRB1 alleles).

3. Clinical Presentation and Staging

Standard Clinical Presentation

The onset of PMR can be insidious or sudden. Patients often report difficulty performing activities of daily living (ADLs), such as rising from a chair, combing their hair, or putting on a jacket.

Clinical Staging/Grading

While there is no formal "staging" system, clinicians utilize the 2012 EULAR/ACR Classification Criteria to grade the probability of PMR:

• Requirement: Age ≥ 50 years, bilateral shoulder pain, and abnormal CRP or ESR.
• Scoring System (Points awarded for):
  • Morning stiffness > 45 minutes (2 pts)
  • Absence of rheumatoid factor or anti-CCP (2 pts)
  • Absence of peripheral joint pain (1 pt)
  • Shoulder involvement (uni- or bilateral) (1-2 pts)
  • Hip involvement (uni- or bilateral) (1 pt)

4. Differential Diagnosis

Distinguishing PMR from other inflammatory and non-inflammatory conditions is critical, as misdiagnosis leads to unnecessary steroid exposure or delayed treatment of underlying malignancy or infection.

Primary Differentials

• Rheumatoid Arthritis (RA): Typically presents with small joint synovitis (MCPs, PIPs) and positive serology (RF/Anti-CCP).
• Late-Onset Spondyloarthritis: Features axial involvement and may show HLA-B27 positivity.
• Giant Cell Arteritis (GCA): PMR is a clinical feature of GCA in 50% of cases. Always screen for headache, jaw claudication, visual changes, or scalp tenderness.
• Malignancy: Paraneoplastic syndromes can mimic PMR. Consider occult malignancy in patients with weight loss and "atypical" PMR symptoms.
• Hypothyroidism: Often presents with diffuse myalgia and fatigue.

5. Diagnostic Testing Protocols

Diagnosis is primarily clinical, supported by laboratory markers of inflammation.

1. Acute Phase Reactants: ESR (Erythrocyte Sedimentation Rate) and CRP (C-Reactive Protein) are typically elevated. Note: 15-20% of patients may have normal ESR/CRP (PMR with normal inflammatory markers).
2. Hematology: Normocytic anemia of chronic disease is frequently observed.
3. Imaging (Optional but Recommended):
   • Ultrasound: Demonstrates subacromial bursitis and biceps tenosynovitis (the "double contour" sign is specific to Gout, but lack thereof helps rule it out).
   • PET/CT: Shows increased FDG uptake in the shoulder and hip girdles; reserved for atypical or refractory cases.

6. Treatment and Management

Standard Pharmacotherapy

The cornerstone of PMR management is low-dose systemic corticosteroids (prednisolone or equivalent).

• Initial Dose: 12.5 mg to 25 mg daily.
• Response: A dramatic improvement in symptoms—often within 24 to 72 hours—is a diagnostic hallmark. Failure to respond should trigger an immediate re-evaluation of the diagnosis.
• Tapering: A slow, individualized taper is required to avoid disease relapse. A typical regimen involves reducing the dose by 2.5 mg every 2–4 weeks until 10 mg is reached, then tapering more cautiously.

Risks and Side Effects of Long-Term Steroid Use

• Bone Health: Osteoporosis/Osteopenia (requires DEXA scan and bisphosphonate prophylaxis).
• Metabolic: Hyperglycemia, weight gain, hypertension, and fluid retention.
• Ocular: Cataracts and glaucoma.
• Adrenal Suppression: Risk of secondary adrenal insufficiency during tapering.

7. Long-Term Prognosis

The prognosis for PMR is generally excellent, but the disease course is often protracted.
* Duration: Most patients require treatment for 1 to 3 years.
* Relapse: Relapses are common during the tapering phase. If a patient relapses, return to the previous effective dose and maintain for a longer period before attempting a slower taper.
* Comorbidity: The primary long-term concern is the potential development of GCA. Patients must be educated on the "red flag" symptoms of GCA (vision changes, jaw claudication) throughout the duration of their PMR treatment.

8. Frequently Asked Questions (FAQ)

1. Is PMR a form of muscle disease?

No. Despite the name, PMR is an inflammatory condition of the joints, bursae, and synovial tissues. The muscles themselves are not primarily affected.

2. How quickly should I expect results from prednisone?

Most patients report significant relief within 24–72 hours. If there is no improvement after one week, the diagnosis should be reconsidered.

3. Can PMR lead to permanent disability?

PMR is generally self-limiting and does not cause permanent joint destruction or deformity. However, untreated, the pain can lead to severe deconditioning.

4. Is it possible to have PMR with normal blood work?

Yes. Roughly 15% of patients with clinically classic PMR have normal ESR and CRP levels.

5. What is the link between PMR and Giant Cell Arteritis (GCA)?

They are considered part of the same disease spectrum. Approximately 15-20% of PMR patients have GCA, and 50% of GCA patients have PMR symptoms.

6. Do I need a muscle biopsy to confirm the diagnosis?

No. Muscle biopsies are not part of the standard diagnostic workup for PMR and are only performed if a primary myopathy (like polymyositis) is suspected.

7. Why is it so hard to stop taking steroids?

The inflammatory process in PMR can persist for years. Tapering too quickly often triggers a "flare" of symptoms, necessitating a return to a higher dose.

8. What lifestyle changes help manage PMR?

Gentle range-of-motion exercises are encouraged to prevent joint stiffness. A diet focused on bone health (calcium/vitamin D) is essential while on corticosteroids.

9. Is PMR hereditary?

There is no clear inheritance pattern, though certain HLA-DRB1 genetic markers are associated with an increased risk of developing the condition.

10. Can PMR recur after it has been fully treated?

Yes, late-onset recurrences are possible, though they are less common after the patient has been in clinical remission for several years.

9. Conclusion

Polymyalgia Rheumatica remains a quintessential "clinical diagnosis." By combining a thorough history of morning stiffness and proximal pain with a cautious approach to steroid management, clinicians can effectively manage the disease and significantly improve the patient's quality of life. Vigilance for GCA and careful monitoring of corticosteroid-related side effects remain the two most critical responsibilities of the managing physician.